Envestnet Asset Management Inc. Sells 9,066 Shares of Icon Plc $ICLR

Envestnet Asset Management Inc. cut its position in shares of Icon Plc (NASDAQ:ICLR) by 5.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 151,086 shares of the medical research company’s stock after selling 9,066 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.19% of Icon worth $26,440,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Artisan Partners Limited Partnership increased its holdings in Icon by 67.4% during the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after buying an additional 2,893,946 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Icon by 739.2% in the 3rd quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock worth $573,526,000 after purchasing an additional 2,886,755 shares during the period. Harris Associates L P bought a new stake in Icon during the 2nd quarter worth approximately $238,256,000. Norges Bank bought a new position in shares of Icon in the second quarter worth $158,639,000. Finally, 1832 Asset Management L.P. raised its holdings in shares of Icon by 587.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock valued at $167,461,000 after acquiring an additional 983,950 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Key Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating with a $105 price target, which is materially above the current price and provides some analyst support for a recovery. Leerink Partners note
• Neutral Sentiment: Short-interest notices in the data feed show anomalous “0 shares / NaN” values for February filings; the reported days-to-cover is 0.0, but the figures appear unreliable and shouldn’t be interpreted as a clear short squeeze signal.
• Negative Sentiment: ICON disclosed an Audit Committee–led internal investigation into accounting practices covering fiscal 2023–2025, and delayed release of Q4 & full-year 2025 results — the core driver of today’s selloff. ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
• Negative Sentiment: Media and legal alerts report that multiple plaintiff firms (Hagens Berman, Rosen Law, Holzer & Holzer, Ademi LLP, Block & Leviton, Johnson Fistel and others) have launched or encouraged inquiries into potential securities claims — increasing the risk of litigation, fees and management distraction. Hagens Berman report
• Negative Sentiment: Coverage and market commentary note that ICON pulled its 2025 outlook amid the probe — raising near-term earnings uncertainty and raising the odds of downward revisions by analysts. Seeking Alpha: ICON pulls 2025 outlook amid ongoing probe
• Negative Sentiment: Price-action coverage highlights a large intraday selloff and heavy volume after the disclosure; investor sentiment and liquidity concerns are likely to persist until the investigation concludes and audited results are released. Investing.com: ICON stock plummets

Analyst Ratings Changes

A number of analysts have recently issued reports on ICLR shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. UBS Group set a $220.00 price target on shares of Icon in a report on Friday, October 24th. Truist Financial reissued a “hold” rating and set a $222.00 target price (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. Leerink Partners reissued a “market perform” rating and issued a $105.00 price target on shares of Icon in a research note on Thursday. Finally, BMO Capital Markets restated a “market perform” rating and set a $100.00 target price on shares of Icon in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $179.93.

Icon Stock Down 39.9%

Shares of Icon stock opened at $80.08 on Friday. The company has a market cap of $6.47 billion, a price-to-earnings ratio of 10.84, a price-to-earnings-growth ratio of 2.79 and a beta of 1.27. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $177.79 and its 200 day moving average is $175.61.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.